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Integrative epigenomics, 
transcriptomics and proteomics 
of patient chondrocytes reveal 
genes and pathways involved in 
osteoarthritis
Julia Steinberg1,10, Graham R. S. Ritchie1,2,3,4, Theodoros I. Roumeliotis1, Raveen L. Jayasuriya5, 
Matthew J. Clark5, Roger A. Brooks6, Abbie L. A. Binch7, Karan M. Shah5, Rachael Coyle1, 
Mercedes Pardo  1, Christine L. Le Maitre7, Yolande F. M. Ramos  8, Rob G. H. H. Nelissen9, 
Ingrid Meulenbelt8, Andrew W. McCaskie6, Jyoti S. Choudhary1, J. Mark Wilkinson  5 & 
Eleftheria Zeggini  1
Osteoarthritis (OA) is a common disease characterized by cartilage degeneration and joint remodeling. 
The underlying molecular changes underpinning disease progression are incompletely understood. We 
investigated genes and pathways that mark OA progression in isolated primary chondrocytes taken 
from paired intact versus degraded articular cartilage samples across 38 patients undergoing joint 
replacement surgery (discovery cohort: 12 knee OA, replication cohorts: 17 knee OA, 9 hip OA patients). 
We combined genome-wide DNA methylation, RNA sequencing, and quantitative proteomics data. We 
identified 49 genes differentially regulated between intact and degraded cartilage in at least two –omics 
levels, 16 of which have not previously been implicated in OA progression. Integrated pathway analysis 
implicated the involvement of extracellular matrix degradation, collagen catabolism and angiogenesis 
in disease progression. Using independent replication datasets, we showed that the direction of 
change is consistent for over 90% of differentially expressed genes and differentially methylated CpG 
probes. AQP1, COL1A1 and CLEC3B were significantly differentially regulated across all three –omics 
levels, confirming their differential expression in human disease. Through integration of genome-
wide methylation, gene and protein expression data in human primary chondrocytes, we identified 
consistent molecular players in OA progression that replicated across independent datasets and that 
have translational potential.
Osteoarthritis (OA) affects in excess of 40% of individuals over the age of 70 years1, and is a leading cause of pain 
and loss of physical function2. The molecular mechanisms underlying OA remain incompletely understood and 
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there is no curative therapy for OA; disease progression culminates in joint replacement surgery. OA is a complex 
disease, with both heritable and environmental factors contributing to susceptibility3.
Cartilage degeneration is one of the key features of OA. Cartilage tissue is readily accessible at joint replace-
ment surgery, providing an opportunity to characterize the molecular processes underpinning disease devel-
opment in the right tissue, both to improve our fundamental understanding of disease biology and to identify 
novel therapeutic opportunities. In recent years, –omics studies in OA have expanded our understanding of 
disease pathogenesis, reviewed in refs 4–7. Here we apply integrated multi-omics (DNA CpG methylation, RNA 
sequencing and quantitative proteomics) in knee OA tissue to obtain a comprehensive molecular portrait of 
cartilage degeneration (Fig. 1a). The fundamental question here addresses the biological processes underpinning 
disease progression within the OA joint, which is of direct clinical relevance to patients suffering from OA. To 
achieve this, we collected individually-matched pairs of cartilage tissue from patients undergoing joint replace-
ment surgery, with one sample demonstrating advanced degenerative change and the other demonstrating little 
or no evidence of cartilage degeneration. The findings were then replicated in several independent populations of 
patients undergoing joint replacement. By integrating all three of methylation, gene expression, and protein abun-
dance data, we discover disease processes with involvement across multiple levels, and reveal novel and robustly 
replicating molecular players with translational potential.
Methods
For full details of methods see Supplementary Methods.
Patients and samples. Osteochondral samples were collected from 38 patients undergoing total joint 
replacement for OA (discovery cohort: 12 knee OA patients; 2 separate replication cohorts: 17 knee OA patients, 
9 hip OA patients). Cartilage was separated from bone and chondrocytes were extracted from each sample. DNA, 
RNA, and protein were extracted from the isolated chondrocytes of each sample. All patients provided full writ-
ten informed consent prior to participation. We obtained two cartilage samples from each patient. Knee samples 
were scored using the OARSI cartilage classification system8, 9: one sample with high OARSI grade signifying 
high-grade degeneration (“degraded sample”), and one sample with low OARSI grade signifying healthy tissue or 
low-grade degeneration (“intact sample”) (Supplementary Fig. S1). Hip samples were classified macroscopically 
and visually as high-grade (“degraded”) or low-grade (“intact”), details see Supplementary Methods.
Proteomics (discovery cohort). LC-MS analysis was performed on the Dionex Ultimate 3000 UHPLC 
system coupled with the high-resolution LTQ Orbitrap Velos mass spectrometer. Proteins were defined as differ-
entially abundant if the absolute median abundance ratio between degraded and intact samples was ≥ 0.75, the 
absolute median abundance ratio was greater than the standard deviation of abundance ratios, and the protein 
was detected in paired samples from at least 5 of 11 patients post-QC.
RNA-seq (discovery cohort). Multiplexed libraries were sequenced on the Illumina HiSeq 2000 (75 bp 
paired-end read length) and individual indexed library BAM files were produced. Reads that passed quality con-
trol (QC) were re-aligned using tophat210, and reads aligning to each gene in each sample were counted using 
the HTSeq package11. Absolute transcript abundance was calculated using the FPKM (fragments per kilobase of 
transcript per million fragments mapped) measure across 15,418 genes post-QC. We used edgeR v3.012 to identify 
Figure 1. Overview of the genes identified in each –omics experiment and their overlap. (a) Schematic view of 
the 3 functional genomics experiments identifying the number of genes shortlisted for each. (b) Venn diagram 
identifying the number of overlapping shortlisted genes from each individual experiment.
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differentially expressed genes, applying a generalized linear model for tissue status (degraded or intact) with indi-
vidual ID as covariate, and defined significance at 5% false-discovery rate (FDR).
Methylation (discovery cohort). Methylation was assayed using the Illumina 450k BeadChip. Data were 
parsed and QCed using ChAMP13; the probe beta values were quantile-normalized using the ‘dasen’ method from 
the wateRmelon package14. Differential methylation on 425,694 probes post-QC was tested using the CpGassoc 
package15, applying a linear model for tissue status at each probe, with individual ID as covariate.
Following previous analyses16, differentially methylated regions (DMRs) were defined as regions of at least 3 
probes with FDR ≤ 5% (DMPs) and no more than 3 non-significant probes, with no more than 1 kb between adja-
cent probes. We used bedtools17 to identify genes overlapping each DMR, extending gene boundaries to include 
likely promoter regions.
For a promoter-level analysis, we used the probe annotations from ChAMP to assign promoter probes to each 
gene. After computing the mean beta value in the promoter of each gene in each sample, we used a paired t-test to 
identify genes with differential promoter-region methylation between degraded and intact samples. Significance 
was set at 5% FDR.
Replication of gene expression and methylation changes. Gene expression and DNA methylation 
in both replication cohorts were measured using the same procedure as for the discovery data. We considered the 
expression of 14,762 genes that passed QC across all datasets; this included 332 of 349 genes with FDR ≤ 5% in 
the knee discovery data.
We considered 416,437 probes that passed QC across all datasets; this included 9,723 of 9,867 probes with 
FDR ≤ 5% in the knee discovery data (“DMPs”).
In silico replication. We carried out an additional replication analysis for gene expression changes using an avail-
able published dataset from the ongoing Research Arthritis and Articular Cartilage (RAAK) study18. This dataset 
comprised a comparison of affected and macroscopically preserved OA cartilage from 33 patients undergoing 
total joint replacement surgery (22 with hip OA, 11 with knee OA), measured using the Illumina HumanHT-12 
v3 microarrays.
Gene set analyses. We tested whether particular biological gene sets were enriched among significant genes 
from each of the RNA-seq, methylation, and proteomics datasets. We used KEGG19, Reactome20, and, separately, 
Gene Ontology (GO) annotations21. Genes annotated to the same term were treated as a “pathway”. Enrichment 
was assessed using a 1-sided hypergeometric test, with significance at 5% FDR. Empirical p-values for the enrich-
ments were obtained from randomisations.
For each gene set, we asked whether the association across the three –omics datasets (calculated as geomet-
ric mean of the p-values) was higher than expected by chance, obtaining empirical p-values from 100,000 
randomisations.
Ethical approval information. The study was approved by Oxford NHS REC C (10/H0606/20). Tissue 
samples were collected under National Research Ethics approval reference 15/SC/0132, South Yorkshire and 
North Derbyshire Musculoskeletal Biobank, University of Sheffield; and under National Research Ethics approval 
reference 11/EE/0011, Cambridge Biomedical Research Centre Human Research Tissue Bank, Cambridge 
University Hospitals, UK. All participants provided written informed consent. All methods were carried out in 
accordance with the relevant guidelines and regulations.
Data availability. All genome-wide summary statistics generated in the discovery component of this study 
are available as Supplementary Tables. All discovery RNA sequencing data are available in the EGA repository, 
https://www.ebi.ac.uk/ega/studies/EGAS00001001203. All discovery methylation data are available in the EGA 
repository, https://www.ebi.ac.uk/ega/studies/EGAS00001001213. The discovery proteomics data has been 
deposited in the PRIDE archive under study ID PXD002014 [publication in process].
Results
We compared the degraded and intact tissue across patient-matched samples.
We identified 209 proteins with evidence of differential abundance (Supplementary Table S1): 90 at higher 
and 119 at lower abundance in the degraded samples. We confirmed the quality of the data using an orthogonal 
label-free approach and, separately, Western blotting (see Supplementary Note).
We identified 349 differentially expressed genes: 296 genes showed higher and 53 lower expression levels in 
the degraded samples (Supplementary Table S2). One of the most strongly down-regulated genes in degraded 
cartilage was CHRDL2. The corresponding protein was also found at lower abundance in degraded cartilage and 
we confirmed its expression in cartilage by immunohistochemistry (Supplementary Fig. S2). CHRDL2 is a bone 
morphogenetic protein (BMP) inhibitor that has been reported to be lost from chondrocytes of the superficial 
zone and shifted to the middle zone in OA cartilage in a targeted study22.
We identified 9,896 differentially methylated probes (DMPs) (Supplementary Table S3), and 271 differentially 
methylated regions (DMRs) composed of multiple differentially methylated CpG sites, overlapping 296 unique 
genes (Supplementary Table S4).
Integration across multiple –omics levels. Methylation, RNA sequencing, and proteomics. We iden-
tified 49 genes with evidence of differential regulation from at least two of the –omics analyses (Supplementary 
Table S5). Three genes demonstrated significant evidence for involvement in OA progression across all three 
levels: AQP1, COL1A1 and CLEC3B (Fig. 1b). All three genes were up-regulated in degraded tissue in both the 
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RNA-seq and proteomics analyses (Fig. 2a). AQP1 and COL1A1 showed a consistent decrease in methylation 
of all CpG probes in their associated DMRs (commensurate with an increase in transcription), while the DMR 
associated with CLEC3B showed evidence of increased methylation. Using IHC we independently confirmed 
the presence of AQP1, COL1A1 and CLEC3B in articular cartilage chondrocytes (Supplementary Fig. S2). We 
also replicated the direction of gene expression change for all three genes in independent data (see below and 
Supplementary Table S6).
Of the 49 genes with evidence of differential regulation on at least two molecular levels, 33 add substan-
tive evidence to genes previously reported and 16 genes (33%) have not previously been implicated in OA 
(Supplementary Table S5).
Proteomics and RNA sequencing. Among the 209 proteins with evidence of differential abundance in 
the proteomics data, 31 were also differentially expressed between degraded and intact samples at the RNA level 
Figure 2. Comparison of changes identified in the –omics experiments. (a) Comparison of the log-fold-
changes between all genes identified in both the proteomics and RNA-seq experiments. Each gene is 
represented as a single point, and the colour corresponds to whether the gene is identified as differentially 
expressed using edgeR in the RNA-seq or proteomics experiments, or both. The trend lines are derived from a 
linear regression in each subset. Positive fold changes indicate increased expression in degraded samples. (b) 
Comparison of RNA-seq log-fold-change and mean promoter region methylation change. The trend lines are 
derived from a linear regression in each subset. Genes are coloured according to the results of the RNA-seq and 
the promoter-region analyses analogously to Fig. 2a.
www.nature.com/scientificreports/
5SCIEnTIfIC REPORTS | 7: 8935  | DOI:10.1038/s41598-017-09335-6
(hypergeometric p = 5.3 × 10−7, Fig. 1b). Twenty-six of these 31 genes showed concordant directions of changes 
at both the protein and RNA level (binomial p = 0.0002). Five genes were over-expressed at the RNA level and less 
abundant at the protein level in the degraded tissue (COL4A2, CXCL12, FGF10, HTRA3 and WNT5B); all five are 
annotated as secreted proteins in the Human Protein Atlas23 (see Supplementary Note).
Using all samples irrespective of tissue status, we found a significant correlation between gene expression 
levels and protein abundance (Spearman’s rho = 0.29, p < 2.2 × 10−16, Supplementary Note and Supplementary 
Fig. S3). Considering the RNA and protein changes in degraded compared to intact samples (Fig. 2a), we also 
identified a significant positive correlation (Pearson’s r = 0.17, p < 2.2 × 10−16). This correlation became substan-
tially higher when we only considered the 31 genes that were differentially expressed in both datasets (Pearson’s 
r = 0.43, p = 0.01).
Methylation and RNA sequencing. Sixteen of the genes overlapping a DMR were also differentially tran-
scribed (Fig. 1b). In the direct comparison of methylation and gene expression using all samples irrespective of 
tissue status, we found the expected negative correlation between promoter region methylation and gene expres-
sion (Spearman’s rho = −0.43, p < 2.2 × 10−16, Supplementary Fig. S3). Based on the comparison of intact to 
degraded cartilage, the log-fold-changes in RNA expression and the differences in mean promoter region methyl-
ation values demonstrated a small but highly significant correlation (Pearson’s r = −0.08, p < 2.2 × 10−16, Fig. 2b, 
Supplementary Table S7). The correlation became substantially higher when we considered the 39 genes with 
significant differences at both the promoter methylation and transcription levels (Pearson’s r = −0.48, p = 0.002).
Replication of gene expression and methylation changes. We found good correlation between the 
global gene expression log-fold changes and the methylation log-fold changes estimated in the discovery and in 
the knee and, separately, hip replication data (Fig. 3a,b, Pearson r 0.5–0.9, p < 10−15) and excellent replication 
rates for differentially expressed genes and probes with differential methylation (Fig. 3c,d, over 90% have same 
direction of change in replication data and at least 47% reach nominal significance, Supplementary Table S8).
We specifically considered the 49 genes with evidence from at least two –omics levels. Of these, 47 had gene 
expression data in the discovery and both replication datasets; the direction of change replicated at nominal sig-
nificance for 36 genes in the knee and for 26 genes in the hip replication data (Supplementary Table S6). Notably, 
the direction of change replicated in at least one of the knee and hip replication datasets at nominal significance 
for 13 of the 16 genes that have not previously been associated with OA (Supplementary Table S6).
We additionally pursued replication in a further independent, published microarray gene expression dataset 
from the RAAK study18. This study used pooled knee and hip samples, as they found good agreement between 
the pooled and joint-stratified analyses18; to increase power, we also used the pooled data as in silico replication. 
Despite the difference in genomics technology (RNA-seq in discovery, microarray in RAAK), we again found 
good agreement of the log-fold-changes for the differentially expressed genes from the discovery data (over 60% 
have same direction of effect, Pearson r in 0.24–0.43 at p ≤ 0.003, see Supplementary Note).
Pathways involved in OA progression. We identified biological processes with consistent evidence of 
involvement in OA progression at multiple levels (Fig. 4, Supplementary Fig. S4, Supplementary Tables S9–S10). 
A strong theme is cartilage matrix regulation, degeneration, and disassembly.
Positive regulation of ERK1/2 cascade, heparin-binding and platelet activation were also enriched at multiple 
molecular levels and are interconnected through common genes (Supplementary Note). We also found enrich-
ment of genes involved in the regulation of angiogenesis at multiple levels, implicating pathways involved in 
blood vessel and nervous system formation (NCAM signaling for neurite outgrowth and PDGF signaling). The 
growth of blood vessels and nerves are closely linked processes that share regulatory mechanisms, including the 
ERK cascade and heparin-binding proteins24. Indeed, histological examination of the samples we investigated 
showed greater blood vessel ingrowth in tissues with more advanced OA (Supplementary Fig. S1).
Drug repurposing potential. To identify existing drugs that could be repurposed for OA, we searched 
Drugbank25 for the 49 genes differentially regulated across at least two –omics levels. We identified ten agents 
with investigational or established actions on nine of the dysregulated proteins, which already have Food and 
Drug Administration Marketing Authorization for use in humans (Table 1). Among them are non-steroidal 
anti-inflammatory agents active against prostacyclin synthase (NSAIDs), which already have marketing author-
isation for the symptomatic treatment of OA. Our search also identified phylloquinone (vitamin K1), an agonist 
of osteocalcin (BGLAP gene). Periostin (POSTN gene), a protein with elevated expression in OA in this study and 
others26–28, is a vitamin K-dependent protein that induces cartilage degeneration29. A recent study has associated 
sub-clinical vitamin K deficiency with knee OA incidence30, adding evidence that this compound could be a 
disease-modifying agent in OA.
Discussion
Characterisation of the molecular landscape of OA is now increasingly feasible and catalyzed by technological 
advances in functional genomics, and the accessibility of the relevant tissue at joint replacement surgery. Indeed, 
the field of functional genomics in OA is now budding31. Previous studies of osteoarthritis have investigated 
methylation32, 33, transcription18, 34–37, or protein expression38, 39 separately, or a combination of up to two of these 
–omics assays16, 40, 41, some with the addition of genetic data42. By contrast, this study provides a systematic anal-
ysis of biological changes involved in OA across genome-wide methylation, gene and protein expression levels.
We identify 49 genes with evidence of changes between intact and degraded cartilage on multiple molecular 
levels, including some novel molecular players in OA. We provide robustly-replicating evidence with convergence 
of all three –omics levels of the involvement of AQP1, COL1A1, and CLEC3B in disease progression.
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AQP1 encodes aquaporin-1, a protein that facilitates water transport across biological membranes. 
Chondrocyte swelling and increased cartilage hydration has been suggested as an important mechanism in OA43. 
AQP1 has been found to be over-expressed in the meniscus of a rat model of knee OA44 and in degraded com-
pared to intact articular cartilage in human patients with knee OA45. CLEC3B encodes tetranectin, which binds 
human tissue plasminogen activator (tPA)46. CLEC3B has previously been found to be up-regulated in OA34, 47. 
COL1A1 is one of several collagens that were differentially abundant at both the RNA and protein levels (see 
Supplementary Table S5). Collagens are the main structural components of cartilage and collagen dysregula-
tion plays an important role in OA48, 49. A recent study identified up-regulation of COL1A1 in synovium from 
humans with end-stage OA, in the synovium of mice with induced OA and in human fibroblasts stimulated 
with TGF-β50. Moreover, the products of AQP1 and CLEC3B are targeted by existing drugs approved for human 
use: aquaporin-1 is inhibited by Acetazolamide, a carbonic anhydrase inhibitor diuretic agent, and tetranectin is 
bound by Tenecteplase, a thromobolytic agent (Table 1).
We further identify previously unreported genes with concordant molecular changes in the degraded tissue on 
multiple levels, and with robust replication in independent datasets. MAP1A and MAP1B were both significantly 
up-regulated in degraded cartilage at the RNA and protein levels (Fig. 2a). These proteins are mainly expressed in 
the brain and involved in regulating the neural cytoskeleton51. Cytoskeletal regulation is thought to be an impor-
tant process in OA52 and recently these proteins were implicated in bone formation53. PXDN was up-regulated at 
the RNA level, confirmed by replication, and overlapped two hypo-methylated DMRs. PXDN encodes peroxida-
sin, which is secreted into the extracellular matrix and catalyses collagen IV cross-linking54. The other replicated 
genes not previously implicated in OA (Supplementary Table S6) have relatively little characterisation.
Figure 3. Replication of gene expression and methylation changes. (a,b) Replication of gene expression changes 
(a) and CpG methylation changes (b) in independent datasets of samples from patients with knee (left) and 
hip (right) OA. Differentially expressed genes (a, DEGs) and differentially methylated probes (b, DMPs) from 
the discovery data are marked in black; DEGs and DMPs that additionally show nominal significance in the 
replication data are marked in red. Inset: correlation between log-fold-changes in discovery and replication 
data. All: all 14,762 genes (a) or 416,437 probes (b) that passed QC in the knee discovery, knee replication, and 
hip replication data. DEGs: 332 of the 349 genes with FDR ≤ 5% in the knee discovery data that also pass QC in 
both replication datasets; DMPs: 9,723 of the 9,867 probes with FDR ≤ 5% in the knee discovery data that also 
pass QC in both replication datasets. All correlation values shown have p < 10−15. (c,d) Directional concordance 
of changes between discovery and replication for the differentially expressed genes (c, DEGs) and differentially 
methylated probes (d, DMPs) from the discovery data. Same dir: proportion of DEGs or DMPs with same 
direction of change in the replication data. Same dir and p ≤ 0.05: among DEGs or DMPs with same direction of 
change in the replication data, proportion of those that reach nominal significance in the replication dataset.
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ANPEP (aminopeptidase E) is a broad specificity aminopeptidase that has previously been detected in the 
synovial fluid of OA patients55 and therefore has potential as a novel OA biomarker. CHRDL2 is a bone morpho-
genetic protein (BMP) inhibitor that has been reported to be lost from chondrocytes of the superficial zone and 
shifted to the middle zone in OA cartilage in a targeted study22. WNT5B, a ligand for frizzled receptors in the 
WNT signaling pathway, has been found to be differentially transcribed in osteoarthritic bone, consistent with 
current understanding that OA is a disease involving both cartilage and bone56.
We identify extracellular matrix organization, collagen catabolism and angiogenesis as biological pathways 
that have significant association with disease progression, in agreement with the consensus findings of previous 
methylation and gene expression studies of OA7. These results corroborate that increased ECM turnover is a cru-
cial component in OA pathogenesis. We found suggestive evidence of a link between some of these pathways and 
genetic OA risk loci (see Supplementary Note, Supplementary Table S11). These signals would not have been iden-
tified directly from GWAS data, highlighting the importance of synthesizing information from multiple molecu-
lar levels to obtain a more powerful integrated view. Follow-up mechanistic studies will be required before causal 
relationships between the identified pathways and OA progression can be established. In the chondrocyte, we 
found little evidence of differential inflammatory pathway activity between the intact and degraded samples57, 58. 
This is not surprising, as all of the patients studied here had a diagnosis of OA and clinically advanced disease in 
at least one location within the joint. Inflammatory mediators are soluble factors present throughout the joint, 
to which both the healthy and the diseased chondrocyte populations are potentially exposed, and for which the 
regulatory molecules may differ compared to the articular cartilage tissue studied here.
Based on our discovery data, we estimate that ~95% of significantly different genes identified in this study 
are true positives (Supplementary Fig. S5). The replication data confirm the high true positive rate and yield 
Figure 4. Significantly enriched gene sets in the integrative analysis. Only gene sets that contain at least 5 genes 
from 2 experiments are shown. Asterisks indicate significant (5% FDR) enrichment for each individual gene-
set in an individual –omics experiment. (a) Fold enrichment for KEGG & Reactome pathways significant at 
5% FDR in the integrative analysis. (b) Fold enrichment for GO terms significant at 5% FDR in the integrative 
analysis.
www.nature.com/scientificreports/
8SCIEnTIfIC REPORTS | 7: 8935  | DOI:10.1038/s41598-017-09335-6
independent strong evidence for multiple novel OA genes. This shows that the gene expression and methylation 
changes identified are robust. Within the constraints of this study, the changes between intact and degraded OA 
cartilage are largely joint-independent. Further work will be needed to narrow down which individual gene-level 
differences between intact and degraded cartilage are joint-independent and which are specific to a joint. This 
work is complementary to previous studies which examined differences in lesion-distant cartilage between 
joints59 or by pooling intact and degraded cartilage16, as neither of these studies examined differences between 
intact and degraded cartilage, and whether such differences are joint-independent.
Notably, this study is a proof-of-concept for integrative deep molecular phenotyping across methylation, gene 
expression, and protein abundance. As such, it was not powered to provide an exhaustive list of molecular targets 
and pathways. Indeed, we estimate that only ~10% of the true differentially expressed genes are statistically sig-
nificant in this study (Supplementary Fig. S5). The sample size could also affect the degree of overlap and agree-
ment between the methylation, gene expression, and protein abundance (this overlap could also be affected by 
difficulties in assigning the effects of methylation changes to genes: for example, it is possible that the expression 
of a gene is affected by methylation changes in a distal enhancer, or that a given gene contains an enhancer region 
for a different gene, and thus methylation of the first gene also affects the expression of the second). Larger sam-
ple sizes will be required for a more powerful characterisation of the molecular changes occurring with disease 
progression. Moreover, investigations of further OA-relevant cell types (including synoviocytes and adipocytes) 
will be necessary to identify disease-related changes in other tissues, and the biological mechanisms specific to 
such tissues.
In summary, the integrative functional genomics approach undertaken here has identified biological changes 
in disease-relevant tissues, highlighting three genes and several pathways that are involved on all three levels 
examined. Moreover, the approach identified nine genes with changes on multiple molecular levels that are 
already targeted by drugs approved for human use, highlighting the potential of discovering targets for inter-
vention. These drugs have established safety profiles and pharmacokinetic data for use in humans, which would 
shorten the investigative pipeline to clinical use in OA. These agents cover a broad range of mechanisms of action 
and represent novel investigational targets for ‘first in disease’ studies of OA progression. Further studies will be 
necessary to comprehensively characterize the molecular signatures of OA.
Gene 
symbol Protein Compound
FDA marketing 
status
Target specific 
mechanism Drug mechanism of action Reference
ANPEP Aminopeptidase N Ezetimibe Prescription binds protein
Anti-hyperlipidemic medication. Used 
to lower cholesterol absorption in the 
small intestine.
Kramer et al. (2005) 
PMID: 15494415
ANPEP Aminopeptidase N Icatibant Prescription inhibits protein
Synthetic peptidomimetic drug 
consisting of ten amino acids, acts as 
a specific antagonist of bradykinin 
B2 receptors. Used in symptomatic 
treatment of acute attacks of hereditary 
angioedema in adults with C1-esterase-
inhibitor deficiency.
Bawolak et al. (2006) 
PMID: 17026984
AQP1 Aquaporin-1 Acetazolamide Prescription inhibits protein
Carbonic anhydrase inhibitor diuretic 
agent. Used for the medical treatment of 
glaucoma, epileptic seizure, idiopathic 
intracranial hypertension, altitude 
sickness, cystinuria, periodic paralysis, 
central sleep apnea, and dural ectasia.
Xiang et al. (2004) PMID: 
15169637
BGLAP Osteocalcin Phylloquinone (vitamin K1)
NA (vitamin) agonist, carboxylates protein
Fat-soluble vitamin necessary for post-
translational modification of certain 
proteins, mostly required for blood 
coagulation.
Schurgers et al. (2001) 
PMID: 11374034
CLEC3B Tetranectin Tenecteplase Prescription binds protein Tissue plasminogen activator (tPA). Used as a thrombollytic agent.
Westergaard et al.46 
PMID: 12694198
CXCL12 Stromal cell-derived factor 1 Tinzaparin Prescription binds protein
Low molecular weight heparin 
(LMWH). Used in the treatment 
and prophylaxis of venous thrombo-
embolism.
Koo et al. (2008) PMID: 
18991783
FGFR2 Fibroblast growth factor receptor 2 Palifermin Prescription binds protein
Recombinant human keratinocyte 
growth factor (KGF). Used to treat oral 
mucositis in patients undergoing cancer 
chemotherapy.
Beaven et al. (2007) 
PMID: 17728847
MAP1A Microtubule-associated protein 1 A Estramustine Prescription disrupts protein
A nitrogen mustard linked to estradiol. 
Used in palliative care of prostatic 
neoplasms.
Stearns et al. (1991) 
PMID: 1647395
PTGIS Prostacyclin synthase
Non-steroidal 
anti-inflammatory 
agents
Prescription inhibits protein COX1 and COX2 inhibitors used in the symptomatic treatment of OA.
Reed et al. (1985) PMID: 
3917545
S100A4 Protein S100-A4 Trifluoperazine Prescription inhibits protein function
A phenothiazine with actions similar 
to chlorpromazine. Used as an 
antipsychotic and an antiemetic.
Malashkevish et al. (2010) 
PMID: 20421509
Table 1. Results of Drugbank25 (www.drugbank.ca) search for therapeutic compounds with current FDA 
marketing authorisation for a clinical indication and a potential role in OA treatment. The mechanisms of 
action and references are taken from Drugbank.
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